Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1974 1
1976 1
1997 2
1998 1
2000 1
2001 1
2002 1
2005 1
2006 3
2007 1
2009 3
2010 2
2011 2
2013 4
2014 3
2017 2
2018 7
2019 5
2020 8
2021 16
2022 9
2023 35
2024 47
2025 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Free PMC article. Clinical Trial.
Connectivity as a universal predictor of tau progression in atypical Alzheimer's disease.
de Bruin H, Groot C, Barthel H, Bischof GN, Blazhenets G, Boellaard R, Boon BDC, Brendel M, Cash DM, Coath W, Day GS, Dickerson BC, Doering E, Drzezga A, van Dyck CH, van Eimeren T, van der Flier WM, Fredericks CA, Fryer TD, van de Giessen E, Gordon BA, Graff-Radford J, Grinberg LT, Hansson O, Hobbs DA, Hoenig MC, Höglinger G, Irwin DJ, Jones PS, Josephs KA, Katsumi Y, La Joie R, Lee EB, Levin J, Malpetti M, McGinnis SM, Mecca AP, Mohanty R, Nasrallah IM, O'Brien JT, O'Dell RS, Palleis C, Perneczky R, Phillips JS, Putcha D, Rabinovici GD, Rahmouni N, Rosa-Neto P, Rowe JB, Rullmann M, Sabri O, Saur D, Schildan A, Schott JM, Schroeter ML, Seeley WW, Servaes S, Sintini I, Smith R, Spina S, Stevenson J, Stomrud E, Strandberg O, Therriault J, Tideman P, Touroutoglou A, Trainer AE, Visser D, Wekselman F, Weston PSJ, Whitwell JL, Wolk DA, Yong K, Pijnenburg YAL, Franzmeier N, Ossenkoppele R. de Bruin H, et al. Among authors: mecca ap. Brain. 2025 Nov 4;148(11):3893-3912. doi: 10.1093/brain/awaf279. Brain. 2025. PMID: 40810361 Free PMC article.
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Mintzer J, Lanctôt KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D; ADMET 2 Research Group. Mintzer J, et al. JAMA Neurol. 2021 Nov 1;78(11):1324-1332. doi: 10.1001/jamaneurol.2021.3356. JAMA Neurol. 2021. PMID: 34570180 Free PMC article. Clinical Trial.
Evidence for the Higgs Boson Decay to a Z Boson and a Photon at the LHC.
Aad G, Abbott B, Abeling K, Abicht NJ, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Acharya BS, Adam Bourdarios C, Adamczyk L, Adamek L, Addepalli SV, Addison MJ, Adelman J, Adiguzel A, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Ahmad A, Ahmadov F, Ahmed WS, Ahuja S, Ai X, Aielli G, Aikot A, Ait Tamlihat M, Aitbenchikh B, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Akiyama D, Akolkar NN, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Albouy GL, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi F, Algren M, Alhroob M, Ali B, Ali HMJ, Ali S, Alibocus SW, Aliev M, Alimonti G, Alkakhi W, Allaire C, Allbrooke BMM, Allen JF, Allendes Flores CA, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alvarez Estevez M, Alvarez Fernandez A, Alves Cardoso M, Alviggi MG, Aly M, Amaral Coutinho Y, Ambler A, Amelung C, Amerl M, Ames CG, Amidei D, Amor Dos Santos SP, Amos KR, Ananiev V, Anastopoulos C, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Anulli F, Aoki M, Aoki T, Aparisi Pozo JA, Aparo MA, Aperio Bella L, Appelt C, Ap… See abstract for full author list ➔ Aad G, et al. Phys Rev Lett. 2024 Jan 12;132(2):021803. doi: 10.1103/PhysRevLett.132.021803. Phys Rev Lett. 2024. PMID: 38277607 Free article.
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP; Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging Initiative. Shirzadi Z, et al. JAMA Neurol. 2023 Dec 1;80(12):1353-1363. doi: 10.1001/jamaneurol.2023.3618. JAMA Neurol. 2023. PMID: 37843849 Free PMC article.
CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME. Lizama BN, et al. Among authors: mecca ap. Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21. Alzheimers Dement. 2024. PMID: 39166791 Free PMC article. Clinical Trial.
MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population.
Wisse LEM, Spotorno N, Rossi M, Grothe MJ, Mammana A, Tideman P, Baiardi S, Strandberg O, Ticca A, van Westen D, Mattsson-Carlgren N, Palmqvist S, Stomrud E, Parchi P, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Wisse LEM, et al. JAMA Neurol. 2024 Oct 1;81(10):1051-1059. doi: 10.1001/jamaneurol.2024.2713. JAMA Neurol. 2024. PMID: 39068668 Free PMC article.
178 results